TABLE 3.
Epitope | Sequencea | IC50 (nM)b | Binding reduction (fold) |
---|---|---|---|
Vif HW8 | HLEVQGYW | 2.9 | |
H1Y | YLEVQGYW | 434 | 150 |
H1Q | QLEVQGYW | 492 | 170 |
Nef IW9 | IRYPKTFGW | 3.5 | |
I1T | TRYPKTFGW | 82 | 23 |
T6M | IRYPKMFGW | 94 | 27 |
Nef MW9 | MHPAQTSQW | 3.7 | |
M1I | IHPAQTSQW | 65 | 18 |
M1V | VHPAQTSQW | 294 | 79 |
Env FW9 | FHEAVQAVW | 7 | |
H2Q | FQEAVQAVW | 8.6 | 1.2 |
V8I | FHEAVQAIW | 13 | 1.9 |
V8F | FHEAVQAFW | 14 | 2 |
V5A | FHEAAQAVW | 15 | 2.1 |
H2Y | FYEAVQAVW | 1,313 | 188 |
Mutations (underlined) that result in substantial binding reductions (>100-fold) are shown in boldface.
Relative binding of the four Mamu-B*17-restricted peptides and common escape variants of the epitopes. IC50 is the concentration of peptide needed to reduce binding of a radiolabeled reference peptide by 50%. The cutoff for physiologically relevant binding is 500 nM (55).